John Charles Thomas
CIK: 0002114900
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)2 (66.7%)
Position reduction
Option Exercises (M)1 (33.3%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
KRYS
Krystal Biotech, Inc.
Officer
Discretionary Trading P&L
Holdings
About Thomas John Charles
Thomas John Charles (SEC CIK 0002114900) files insider reports with the SEC as EVP, General Counsel of Krystal Biotech, Inc. (KRYS).
Signal8 holds 3 ownership filings by Thomas John Charles (1 Form 3, 2 Form 4), filed between Mar 6, 2026 and Jun 26, 2026. Those filings report 3 transactions, from May 26, 2026 to Jun 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Thomas John Charles's filings is in PITTSBURGH, PA.
Recent filings by Thomas John Charles
Other insiders filing for Krystal Biotech, Inc. (KRYS)
- ROSSI DINO A, Director
- Sutherland Everett Rand, Director
- Mazzacco Catherine, Director
- Mason Christopher, Director
- JANNEY DANIEL, Director
- Gangolli Julian S, Director